A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study

Greenberg, Eyal; Besser, Michal J.; Ben-Ami, Eytan; Itzhaki, Orit; Zikich, Dragoslav; Levy, Drorit; Kubi, Adva; Eyal, Eran; Onn, Amir; Cohen, Yinon; Barshack, Iris; Schachter, Jacob; Markel, Gal

doi:10.3109/1354750x.2013.816777

Cited by 39 publications

(36 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to mRNAs and proteins, miRNAs are not involved in complex post-transcriptional and post-transcriptional modification. Considering the limitations of condition and time for tissue sampling (Freidin et al 2012), circulating miRNAs are optimal prog- nostic biomarkers for cancer (Sanfiorenzo et al 2013;Chen et al 2013b;Lin et al 2013;Greenberg et al 2013;Kim et al 2013). However, further studies should be conducted before miRNA can be extensively used in clinical applications.…”

Section: Discussionmentioning

confidence: 99%

“…The unique expression profile of circulating miRNA may function as the fingerprint of different diseases because miRNAs are highly stable in serum and plasma (Chen et al 2008). Circulating miRNA has been considered as a potential non-invasive biomarker in tumor diagnosis and prognosis (Sanfiorenzo et al 2013;Chen et al 2013b;Lin et al 2013;Greenberg et al 2013;Kim et al 2013;Rani et al 2013).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Cao

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

MicroRNA (miRNA) is a type of small non-coding RNA molecule that has important roles in cancer initiation, promotion and progression by negatively regulating gene expression. In this study, we explored the role of miRNAs in the prognosis of patients with non-small cell lung cancer (NSCLC). The miRNA expression profiles were determined in 5 pairs of NSCLC and paracancerous tissues (3 adenocarcinomas and 2 squamous cell carcinomas). Aberrantly expressed miRNAs were validated by quantitative real-time PCR (qRT-PCR) in 61 pairs of NSCLC and paracancerous tissues. Differentially expressed miRNAs were further analyzed in sera from 94 healthy subjects and 94 advanced NSCLC patients receiving platinumbased chemotherapy. Three miRNAs (miR-19b, miR-146a, and miR-223) were significantly dysregulated in NSCLC tissues (P < 0.05). High miR-19b and low miR-146a expression in NSCLC tissues were associated with higher TNM stage, lymph node metastasis and poorer survival (P < 0.05). The serum levels of miR-19b in NSCLC patients were significantly higher (P < 0.001), whereas serum levels of miR-146a were significantly lower (P < 0.001), compared with those in controls. Serum levels of miR-19b and miR-146a were associated with overall survival of NSCLC patients (P < 0.05). Patients with low serum level of miR-19b and high serum level of miR-146a achieved a higher overall response rate and longer survival time (P < 0.05). These data suggest that miR-19b and miR-146a are potential biomarkers for the prediction of survival and response to chemotherapy in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Cao

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Among those ncRNA species, miRNA has been primarily studied, so far, mainly because of proven stability in the circulation and availability of specific and sensitive detection assays [8,9]. In malignant melanoma, several studies analyzed clinical utility of circulating microRNA [10,11]. However, clinical relevance of other ncRNA in the circulation of melanoma patients has not yet been investigated.…”

Section: Introductionmentioning

confidence: 98%

Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients

Kuhlmann¹,

Wimberger²,

Wilsch³

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…Many tumor types have been evaluated for differential miRNA expression, including ovarian carcinomas, breast cancer, cervical cancer, non-small cell lung cancer, leukemias, colorectal tumors, squamous cell carcinoma, and hepatocellular carcinoma [21–28]. Use of miRNAs in support of other diagnostic methods is currently in its infancy, with miRNA signatures having been developed in people to distinguish melanoma and metastatic breast cancer from healthy controls and higher risk groups in breast cancer and prostate cancer [29–32]. There are few reports of miRNA involvement in cancer of veterinary patients, but interest in this area will likely increase with the rapid growth of this topic in human medicine [33–35].…”

Section: Introductionmentioning

confidence: 99%

A comparison of microRNA expression profiles from splenic hemangiosarcoma, splenic nodular hyperplasia, and normal spleens of dogs

et al. 2016

View full text Add to dashboard Cite

BackgroundSplenic masses are common in older dogs; yet diagnosis preceding splenectomy and histopathology remains elusive. MicroRNAs (miRNAs) are short, non-coding RNAs that play a role in post-transcriptional regulation, and differential expression of miRNAs between normal and tumor tissue has been used to diagnose neoplastic diseases. The objective of this study was to determine differential expression of miRNAs by use of RNA-sequencing in canine spleens that were histologically confirmed as hemangiosarcoma, nodular hyperplasia, or normal.ResultsTwenty-two miRNAs were found to be differentially expressed in hemangiosarcoma samples (4 between hemangiosarcoma and both nodular hyperplasia and normal spleen and 18 between hemangiosarcoma and normal spleen only). In particular, mir-26a, mir-126, mir-139, mir-140, mir-150, mir-203, mir-424, mir-503, mir-505, mir-542, mir-30e, mir-33b, mir-365, mir-758, mir-22, and mir-452 are of interest in the pathogenesis of hemangiosarcoma.ConclusionsFindings of this study confirm the hypothesis that miRNA expression profiles are different between canine splenic hemangiosarcoma, nodular hyperplasia, and normal spleens. A large portion of the differentially expressed miRNAs have roles in angiogenesis, with an additional group of miRNAs being dysregulated in vascular disease processes. Two other miRNAs have been implicated in cancer pathways such as PTEN and cell cycle checkpoints. The finding of multiple miRNAs with roles in angiogenesis and vascular disease is important, as hemangiosarcoma is a tumor of endothelial cells, which are driven by angiogenic stimuli. This study shows that miRNA dysregulation is a potential player in the pathogenesis of canine splenic hemangiosarcoma.

show abstract

A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study

Abstract: This approach is independent of tumor heterogeneity and is expected to have superior biomarker performances.

Cited by 39 publications

References 31 publications

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients

A comparison of microRNA expression profiles from splenic hemangiosarcoma, splenic nodular hyperplasia, and normal spleens of dogs

Contact Info

Product

Resources

About